Market Analysis

Market Analysis

Most cancers are the second leading cause of dying global. It’s crucial to take into account that most cancers aren’t one disease it’s more than 200 most cancers illnesses involved. All distinctive and unique diseases, which require distinctive procedures for treatment. Treatments that paintings for some cancers don’t work for others and every so often those remedies surely prevent operating. Simplest worldwide research will beautify our expertise of cancer and help us find and increase better, extra effective treatments. And best a global search for answers will assist us become familiar with this sickness. . The conference will provide with a tremendous opportunity for the delegates from Universities and Institutes to interact with the sector elegance Scientists and enterprise specialists operating in the discipline of cancer (or) oncology.

World Cancer 2023 may even discover the brand new ideas and ideas on worldwide scale and the subjects most cancers Biology & Genetics, Organ-defined Cancers, Oncology: Sub-Specialities, Radiation Oncology, Surgical Oncology, most cancers & Stem cell therapy, Precision most cancers medicinal drug & Oncology, most cancers Biomarkers, most cancers Epidemiology, cancer Prevention & research, most cancers therapy & remedies, most cancers Pharmacology, cancer Vaccines, most cancers Immunology & Immunotherapy, Oncology Nursing and Care, Complementary & alternative strategies and most cancers, most cancers focus and Survival, most cancers: life-style and vitamins, most cancers: psychological & Social elements.

Glance at the market:
The global cancer diagnostics market size was valued at USD 160.5 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.89% from 2022 to 2030. Increasing number of cancer cases globally is one of the major factors contributing to industry growth during the forecast period. Technological advancements in diagnostic tests are further expected to fuel industry growth. Moreover, supportive government initiatives and rising awareness are some additional factors anticipated to boost the growth during the forecast period. For instance, the Biden-Harris administration has set a goal of decreasing the cancer mortality rate by 50% over the following 25 years and enhancing the knowledge of people living with and surviving tumors.

COVID-19 has placed an unprecedented strain on healthcare systems globally. It has led to challenges in offering care while minimalizing the spread of the virus and created a great demand for hospital resources. Healthcare systems across the world have struggled to adjust to the challenges posed by the COVID-19 pandemic. Subsequently, surgeons have seen a lessening number of elective procedures executed since the pandemic began. Planned oncology surgeries have been affected by this rescheduling of non-urgent elective operations. Patients with tumors are at a high risk of infection. Furthermore, morbidity and mortality from COVID-19 are increased in patients with cancer. As per the report by the American Society of Clinical Oncology in March-July 2020 in comparison with 2019, there was a considerable decrease in biopsies, tumor screenings, office visits, therapy, and surgeries. In April 2020, at the peak of the pandemic, screenings for colon, breast, lung, and prostate cancers were lower by 75%, 85%, 56%, and 74%, respectively. Additionally, in March 2020 alone, the COVID-19 pandemic forced the delay of more than 800 appointments for the screening of lung cancer. Even after the screening resumed to a normal schedule, the percentage of new patients screening remained low.

Cancer is one of the leading causes of death across the world and the prevalence of the disease has been escalating at an alarming rate. Therefore, healthcare professionals are focusing on the development of effective screening and treatment solutions to check prevalence levels. Early screening increases the success rate of treatment regimens. As a result, healthcare agencies and market players, through various awareness programs, are promoting routine check-ups and screenings. For instance, in March 2022, HHS announced funding of USD 5 million to improve equity in the screening of cancer at health centres.

The Global Oncology burden is projected to reach 28.4 million cases in 2040, a 47% upsurge from 2020. Thus, rise in the incidence is anticipated to boost the adoption of cancer diagnostic products. In April 2022, the Precision Cancer Consortium (PCC) collaborated with pharmaceutical companies by permitting access to comprehensive testing for all cancer patients globally. The PCC drives diversity of initiatives aimed at growing patient access to precision diagnostics using wide-ranging genomic testing including NGS. The founding members of PCC include Novartis, Bayer, Roche, and GlaxoSmithKline.

Technological advancements in diagnostic testing are further expected to fuel market growth during the forecast period. For instance, in November 2021, Hologic, Inc. announced the commercial accessibility of the Genius Digital Diagnostics System in Europe. The system is the next-generation cervical cancer screening, which combines the deep learning-based AI with innovative volumetric imaging technology to help identify the cervical cancer cells and pre-cancerous lesions in women. In addition, in March 2022, Hartford HealthCare and Ibex Medical Analytics announced a research initiative involving Ibex's ‘Galen Breast’, an Artificial Intelligence solution helping doctors deliver high-quality enhanced care and screening for breast cancer patients. Thus, such growing initiatives by the key players are expected to boost the industry growth in the near future.

Rising number of programs to raise awareness about malignant tumor screening by various organizations is a key factor responsible for the increased demand for diagnostic products worldwide. Collaborations and partnerships undertaken by the National Cervical Cancer Coalition, the WHO, the CDC, and the U.S. Preventive Services Task Force for increasing cervical cancer screening are expected to boost industry growth during the study period. Moreover, several countries have undertaken measures to increase screening for early screening and help the existing patients. For instance, the Indian government has initiated the Ayushman Bharat and the Prime Minister’s National Relief Fund for patients who require assistance during the treatment.

The current improvements inside the most cancers treatments & most cancers care are accelerating. A cluster of progressive remedies, frequently blended with other new or current medicines, and regularly associated with biomarkers, are emerging from the research and development pipeline.

Over the last 5 years, 70 new oncology treatments were released and are getting used to deal with over 20 special tumour types.

The global most cancers biomarker marketplace length was worth USD 10.3 billion inside the 12 months 2016 and is estimated to reach a value of USD 33.7 billion by way of 2025, growing with CAGR of 14.3 %. Growing prevalence of malignancies coupled with increasing consciousness on improvement of focused treatment options is a prime component affirming boom of this market.

Global cancer drugs marketplace accounted for $seventy eight, 238.9 million in 2015. The most cancers drugs marketplace is driven by using the growing occurrence of numerous sorts of most cancers, increasing demand of biological and centered drug treatment plans, non-stop patent expiry of key cancer pills and the growing impact of bio similars. Global Oncology/most cancers drugs marketplace is anticipated to garner $111.9 billion by using 2020, registering a CAGR of seven.1% in the course of the forecast length 2014 to 2020. Recent development in organic therapies has widened the scale of healing goals for remedy of most cancers with the identification of tumour mobile particular genes.

The global most cancers diagnostics market is segmented primarily based on era, application, and region.

This document studies the global cancer diagnostics market for the forecast period of 2015 to 2020. This market is expected to attain $thirteen.1 Billion by way of 2020 from $7.1 Billion in 2015, and is poised to grow at a CAGR of 12.9% at some stage in the forecast length

Product Insights:

The consumables segment held the largest share of over 60.0% in 2021 and is anticipated to maintain this position throughout the forecast period. Increasing usage of consumables, increased R&D expenditure, an increase in the geriatric population, and the launch of technologically advanced diagnostic kits and reagents are fuelling the growth of the segment.

In January 2020, Sysmex Corporation launched ipsogen JAK2 DX reagent. It is a gene testing kit, which measures the JAK2V617F mutation quantitatively, which is used for the screening of blood cancers. In addition, in January 2020, the product gained health insurance coverage, becoming Japan’s first diagnostic product to be covered. Moreover, the tests using this reagent will be covered under the health insurance. This is anticipated to boost the opportunities for more patients to receive testing.

In September 2022, Precipio, Inc. has signed a distribution agreement for HemeScreen with a major distribution partner in the U.S. The company continues to carry out its HemeScreen distribution expansion strategy of a multi-pronged method by targeting the national and regional hospital networks, physician-owned laboratories, and reference labs. The diversity of channel partners and distributors engaging with Precipio augments its market potential.

Technology Insights

The IVD testing held the largest share of over 60.0% in 2021 owing to factors such as increasing adoption of in-vitro diagnostics. Increasing number of in vitro diagnostics products being launched by the major market players is also fueling the growth of the market. For instance, in Feb 2022, Invitee launched LiquidPlex Dx and FusionPlex Dx in Europe. The product launch will increase patients’ access to cancer diagnostics in Europe. Moreover, in June 2022, Biocartis Group NV launched its fully automated Idylla GeneFusion Panel for non-small cell lung cancer. The panel is designed for use in clinical laboratories and provides complete testing results within 180 minutes, considerably faster than recently available testing methods, which frequently take days or even weeks for the results.

The IVD testing segment is further sub-segmented into polymerase chain reaction, in situ hybridization, immunohistochemistry, next-generation sequencing, microarrays, flow cytometry, immunoassays, and other IVD testing technologies. PCR held the largest market share in 2021 as PCR-based techniques need comparatively simple infrastructure and instrumentation, utilize only small amounts of biological material, and are extremely compatible with the clinical routine. NGS is expected to grow at the fastest rate during the review period.

Biopsy technique is expected to be the fastest-growing segment during the forecast period. Biopsy is one of the most significant screening techniques for cancer detection. This screening technique has revolutionized breast, prostate and skin cancer diagnoses to a great extent. An increase in the global number of cancer cases has spurred the demand as well as supply of biopsy devices.

Furthermore, a global shift in consumer preference toward minimally invasive surgical procedures owing to growing awareness about associated benefits such as faster recovery times, smaller incisions, and reduced pain and scarring further propel investment in the space.

Screening Type Insights:

The laboratory tests segment held the largest share of over 25.0% in 2021 owing to rise in the prevalence of cancer. While conducting laboratory tests for cancer, samples of urine, blood, or other body fluids or tissues are examined for tumor markers or abnormal cells that help determine if an individual has a precancerous condition or cancer. Laboratory tests are also used to screen high-risk patients, identify various treatment options, pinpoint disease stage, and evaluate if the disease is responding to treatment. These tests help determine if a patient has cancer recurrence, or a new tumor has developed.

Rising number of research activities undertaken by various academic and research organizations is also expected to fuel the market growth during the forecast period. For instance, in August 2021, The Cancer Prevention and Research Institute of Texas (CPRIT) announced new 74 cancer research and grants on prevention for over USD 112 million. The projects approved include 7 prevention awards, 65 academic research grant awards, and research for the development of 2 product awards, which is granted to 16 companies and institutions across the state. These awards will increase clinical trial access, support ground-breaking research, and deliver much needed cancer screening.

The biopsy segment is expected to grow at the fastest rate during the forecast period due to various benefits associated with the test, including early detection of cancer. In addition, biopsy helps determine how aggressive the disease is and how likely it is to spread to other organs. A biopsy helps in the selection of a specific treatment plan, depending on the spread of tumor. Furthermore, key operating players have introduced innovative products for market expansion, thus driving the market. For instance, in February 2021, Twist Bioscience Corporation launched Twist NGS Methylation Detection System for liquid biopsy cancer analysis and epigenetic studies.

Application Insights:

The others segment dominated the market and held a share of over 20.0% in 2021. The breast cancer segment held the second-largest share in 2021. Growth of R&D in advanced screening tools for breast cancer is anticipated to boost the segment growth significantly. In March 2022, Paige launched Paige Breast Lymph Node, an Artificial Intelligence medical device software, which helps pathologists identify if breast cancer has grown to lymph nodes.